Pharmaceutical Products

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases. At McKesson, we are here to help you navigate the biosimilar landscape and identify opportunities for your health system to expand treatment options for patients with complex diseases and realize substantial cost savings on expensive therapies.

Get access to more than 22,000 distinct, active generic drugs and generic drug raw materials in our product catalog, as well as our branded drug sourcing network supported by long-standing supplier relationships with more than 500 drug manufacturers competitive prices, through our comprehensive suite of purchasing and distribution solutions for branded and generic products.

For patients facing rare diseases, high-cost medications known as orphan drugs can offer a chance at remission, recovery, or an improved quality of life - and for health systems that offer these advanced therapies, they can become a valuable differentiator in achieving more for their business of pharmacy.

Cell and gene therapies (CGT) are delivering transformative care for patients – but getting them to market requires specialized expertise. At McKesson, we bring unparalleled experience in every stage of the CGT life cycle, from early clinical development through commercialization. We’ll partner with you to address your unique priorities, anticipate possible challenges and offer real-time solutions. All to enable you to realize the full potential of your therapy.

At McKesson, we play a critical role in helping make medication and supplies available to our customers and patients across North America. With our deep expertise in pharmaceutical distribution, supply chain analytics, and market access dynamics, we are committed to helping address the multitude of challenges contributing to drug shortages.